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Abstract
Background: Somatic calreticulin (CALR), Janus kinase 2 (JAK2), and thrombopoietin receptor (MPL) mutations
essentially show mutual exclusion in myeloproliferative neoplasms (MPN), suggesting that they activate common
oncogenic pathways. Recent data have shown that MPL function is essential for CALR mutant-driven MPN. However,
the exact role and the mechanisms of action of CALR mutants have not been fully elucidated.
Methods: The murine myeloid cell line 32D and human HL60 cells overexpressing the most frequent CALR type 1 and
type 2 frameshift mutants were generated to analyze the first steps of cellular transformation, in the presence
and absence of MPL expression. Furthermore, mutant CALR protein stability and secretion were examined using
brefeldin A, MG132, spautin-1, and tunicamycin treatment.
Results: The present study demonstrates that the expression of endogenous Mpl, CD41, and the key megakaryocytic
transcription factor NF-E2 is stimulated by type 1 and type 2 CALR mutants, even in the absence of exogenous MPL.
Mutant CALR expressing 32D cells spontaneously acquired cytokine independence, and this was associated with
increased Mpl mRNA expression, CD41, and NF-E2 protein as well as constitutive activation of downstream signaling and
response to JAK inhibitor treatment. Exogenous expression of MPL led to constitutive activation of STAT3 and 5, ERK1/2,
and AKT, cytokine-independent growth, and reduction of apoptosis similar to the effects seen in the spontaneously
outgrown cells. We observed low CALR-mutant protein amounts in cellular lysates of stably transduced cells, and this was
due to accelerated protein degradation that occurred independently from the ubiquitin-proteasome system as well as
autophagy. CALR-mutant degradation was attenuated by MPL expression. Interestingly, we found high levels of mutated
CALR and loss of downstream signaling after blockage of the secretory pathway and protein glycosylation.
Conclusions: These findings demonstrate the potency of CALR mutants to drive expression of megakaryocytic
differentiation markers such as NF-E2 and CD41 as well as Mpl. Furthermore, CALR mutants undergo accelerated
protein degradation that involves the secretory pathway and/or protein glycosylation.
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Background
Using exome sequencing, calreticulin (CALR) frame-
shift mutations were discovered in myeloproliferative
neoplasms (MPN) and shown to be restricted to essen-
tial thrombocythemia (ET) and primary myelofibrosis
(PMF) [1, 2]. Both neoplasms involve striking abnor-
malities of megakaryocytes [3, 4]. CALR, Janus kinase 2
(JAK2) V617F, and thrombopoietin receptor (MPL)
mutations were mutually exclusive, suggesting that they
all activate the JAK2-STAT signaling pathway to trans-
form hematopoietic stem cells. While only exceptional
cases of CALR-mutant polycythemia vera (PV) have been
described in cases that were negative for JAK2V617F [5],
15–24 % and 25–35 % of patients with ET and PMF,
respectively, carry a CALR mutation [3]. CALR frameshift
mutations are classified according to the length of the
somatic deletion or insertion in exon 9 of the CALR gene.
Until now, 36 types of CALR mutants have been observed
in MPN [2]. All of these mutants lead to a 1-bp frameshift
and loss of the KDEL sequence and the original CALR
stop codon [2]. The most frequent variants, the type 1
(c.1092_1143del) and type 2 (c.1154_1155insTTGTC) mu-
tations, representing either a 52-bp deletion (p.L367fs*46;
del52) or a 5-bp insertion (p.K385fs*47; ins5), respectively,
account for approximately 80 % of all CALR mutations
[1, 2]. Type 1 and 2 CALR mutations have been shown
to carry prognostic relevance [6], but this was not
found by all groups [7].
CALR is a chaperone which is localized in the endoplas-
mic reticulum (ER) and exhibits an N-terminal ER-signal
sequence, a N-, P-, and C-domain, and the ER retrieval
sequence KDEL [8]. CALR function regulates protein fold-
ing and quality control processes [9]. Furthermore, CALR
strongly affects calcium (Ca2+) homeostasis in the ER/
cytoplasm and thus Ca2+-dependent signaling through its
P-domain (low Ca2+ capacity; high Ca2+ affinity) and C-
domain (high Ca2+ capacity; low Ca2+ affinity) [8]. The
modified C-terminus in CALR frameshift mutants com-
prises several additional triplets that were formerly part of
the 3′UTR in wild-type (WT) CALR. Importantly, a large
proportion of negatively charged amino acids in the C-
domain of WT CALR converts into positively charged
amino acids, abolishing proper Ca2+-binding [10].
While the function of CALR mutants in ET and PMF
has remained unclear, recently, Marty et al. and Chachoua
et al. have highlighted the necessity of the thrombopoietin
(TPO) receptor MPL and its N-glycosylation to be essen-
tial for cellular transformation [11, 12]. Marty et al. estab-
lished a retroviral mouse model of del52 and ins5, closely
reflecting an ET phenotype and, in the case of CALR
del52, also the progression to myelofibrosis [12]. Further-
more, two research groups have shown physical inter-
action of CALR mutants and MPL and the necessity of
the positive electrostatic charge of the novel C-terminus
for this interaction [13, 14]. Araki et al. presented a model
by which the P-domain in WT CALR blocks MPL inter-
action [13]. This inhibitory function of the P-domain is
abolished by the novel C-terminus in mutant CALR, thus
enabling the N-domain to interact with the extracellular do-
main of MPL and leading to its dimerization and activation.
In the present study, we investigated the impact of
CALR mutants on megakaryocytic transcription factors
implicated in endogenous Mpl and CD41 expression.
Moreover, we assessed CALR-mutant protein stability
and secretion. We further confirmed MPL-dependence
of CALR mutant-driven cell transformation and protec-
tion from apoptosis, as well as activation of critical
signaling proteins including STAT5, STAT3, AKT, and
ERK1/2. Collectively, our findings extend our under-
standing of CALR frameshift mutants’ cellular character-
istics involved in pathogenesis and suggest that CALR
mutants support megakaryocytic differentiation by MPL-
dependent and MPL-independent mechanisms.
Methods
Patient samples and cDNA
RNA from patients carrying WT CALR or the ins5 mutant
was isolated from the peripheral blood of MPN patients
after written informed consent and ethics committee ap-
proval (EK2127/12). Complementary DNA (cDNA) from a
patient with CALR del52 mutant was provided by Prof. S.
Schnittger and Prof. T. Haferlach (Munich). The patient
gave written informed consent to research studies, and the
study was approved by the local ethics committee (05117)
and adhered to the tenets of the Declaration of Helsinki.
The wild-type and mutant CALR cDNA fragments used
for vector cloning were obtained from patients’ RNA by
reverse transcription polymerase chain reaction (RT-PCR)
with random primers.
Reagents and antibodies
The proteasome inhibitor MG132, tunicamycin, and
brefeldin A (BFA) were purchased from Sigma-Aldrich
(St. Louis, MO, USA). Ruxolitinib (LC Labs, Woburn, MA,
USA), spautin-1 (Selleckchem, Houston, TX, USA), and
tunicamycin were dissolved in DMSO. BFA was dissolved
in 100 % methanol. TransIT-LT1 (Mirus, Madison, WI,
USA) was used to transfect HEK293T cells according to the
manufacturer’s instructions. Antibodies used in our study
included polyclonal rabbit anti-mouse/human phospho-
STAT5 (Tyr694), polyclonal rabbit anti-mouse/human
phospho-STAT3 (Tyr705), monoclonal rabbit anti-mouse/
human phospho-AKT (Ser473) (193H12), polyclonal
rabbit anti-mouse/human phospho-p44/42 MAPK (Erk1/
2) (Thr202/Tyr204), polyclonal rabbit anti-mouse/human
p44/42 MAPK (Erk1/2), monoclonal rabbit anti-mouse/
human LC3B (3868s) and monoclonal rabbit anti-
mouse/human STAT3 (D3Z2G), which were obtained
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from Cell Signaling/New England Biolabs (Frankfurt,
Germany). The mouse monoclonal HA-probe antibody
(sc-7392), polyclonal goat anti-mouse/human AKT1/2
(sc-1619), monoclonal mouse anti-mouse/human NF-
E2 (sc-365083), monoclonal mouse anti-mouse/human
GAPDH (sc-32233), and polyclonal rabbit anti-mouse/
human DNMT3B antibody (sc-20704) were ordered
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Monoclonal rabbit anti-mouse/human calreticulin anti-
body (EPR3924) from Merck Millipore (Darmstadt,
Germany) was used for total calreticulin detection. The
mouse monoclonal antibody CAL2 (Dianova, Hamburg,
Germany) against the novel C-terminal of the CALR
mutants was used for CALR mutant (CALR mut) de-
tection. The mouse monoclonal anti-flag antibody M2
(F3165) was ordered from Sigma-Aldrich. The antibody
against STAT5A/B was a kind gift from Richard
Moriggl (Ludwig Boltzmann Institute for Cancer Re-
search (LBI-CR), Vienna, Austria) and was originally
generated by Eurogentec, Cologne, Germany. The CD41-
APC-eFluor®780 (MWReg30) antibody and its isogenic
control (eBRG1) were obtained from eBioscience (San
Diego, CA, USA). Polyclonal goat anti-rabbit immuno-
globulins/HRP (P0448), polyclonal goat anti-mouse
immunoglobulins/HRP (P0447), and polyclonal rabbit
anti-goat immunoglobulins/HRP (P0160) antibodies were
purchased from DAKO (Hamburg, Germany).
DNA constructs and vectors
The flag-tagged cDNA of WT CALR, del52, and ins5 were
cloned into the pMSCV-IRES-GFP vector and pcDNA5/
FRT/TO vector (Life Technologies – Thermo Fisher Sci-
entific, Paisely, UK) by Gateway cloning system (Life
Technologies – Thermo Fisher Scientific). In case of the
WT CALR, the KDEL sequence was cloned behind the
flag-tag sequence. The cDNA of human MPL in the
pMSCV-neo vector was kindly provided by Rebekka
Schneider-Kramann. The C-terminally yellow fluorescent
protein (YFP)-tagged cDNA of WT CALR, del52, and
ins5 were cloned into the pMSCV-IRES-puromycin vec-
tor, and the KDEL sequence was cloned following the
YFP-tag only in the WT CALR expression vector.
Cell culture and retroviral transduction
32D cells were cultured in RPMI 1640 medium (Life Tech-
nologies – Thermo Fisher Scientific) supplemented with
10 % fetal bovine serum (FBS), 25 U/ml penicillin/strepto-
mycin (Life Technologies – Thermo Fisher Scientific) and
10 % Walter and Eliza Hall Institute (WEHI) supernatant
as source of interleukin-3 (IL-3). HEK293T cells were cul-
tured in Dulbecco’s Modified Eagle’s Medium (DMEM,
Biochrom, Berlin, Germany) supplemented with 10 % FBS
and 25 U/ml penicillin/streptomycin. The HL60e cell line
stably expressing ecotropic receptor was a gift from Herbert
Strobl (Vienna) generated by Bradley Fletcher (FL,
USA). The retroviral transduction was performed as
previously described [15]. Briefly, Plat-E-packaging cells
were transfected with pMSCV-IRES-GFP or pMSCV-
IRES-neo/puro vectors containing the genes of interest
and supernatants were collected after 24 and 48 h.
Stable 32D cell lines were generated by three rounds of
retroviral spin onto RetroNectin-coated (Takara Bio
Europe/Clontech, France) six-well plates followed by
selection by means of flow cytometry for GFP or G418/
puromycin (InvivoGen, CA, USA) treatments.
Proliferation assay
32D cells were plated in triplicate at a density of 2 ×
105 cells/ml and were cultured in WEHI-free RPMI
medium. Living cells were manually counted every 24 h in
a standard hemocytometer, excluding dead cells by trypan
blue staining.
Immunophenotypic analysis
Staining of 32D CALR cells for the presence of membrane-
localized CD41 was performed using a Gallios flow cyt-
ometer (Beckman Coulter, Krefeld, Germany). Data were
evaluated using FlowJo data analysis software (OR, USA).
Preparation of cell lysates, SDS-PAGE, and
immunoblotting
Cell lysates were produced with RIPA buffer containing
50 mM Tris pH 7.4, 150 mM sodium chloride, 1 mM
EDTA, 1 % Triton-X, 15 % glycerol, 0.5 % sodium deox-
ycholate, and protease/phosphatase inhibitors. Denatur-
ing of protein lysates was done at 65 °C for 5 min and
separated by SDS-PAGE and transferred to polyvinylidene
difluoride (PVDF) membrane (GE Healthcare, Frankfurt,
Germany). Western blotting was performed overnight in
Towbin transfer buffer (3 g Tris, 14.4 g glycine, 5 %
methanol per liter ddH2O) at 100 mA. Ten percent BSA
in TBS-I buffer (20 mM Tris–HCl, pH 7.6, 137 mM NaCl,
0.05 % IGEPAL) was used for membrane blocking. The
primary antibody (1:1000) was incubated overnight at
4 °C, and the secondary antibody conjugated to HRP
(1:2000) for 45 min with three times washing in be-
tween. Proteins were detected via chemoluminescence
(Fusion SL, PeqLab). ImageJ software was used for pro-
tein quantification analysis [16].
Ubiquitination assay
HEK293T cells were transiently transfected with 3 μg
pcDNA5 vector expressing CALR WTand CALR del52 to-
gether with or without 4 μg pcDNA3-ubi-HA vector using
TransIT-LT1 reagent (Mirus, Madison, USA). After 24 h,
the medium was discarded and replaced by fresh DMEM
containing 10 μM MG132 for 20 h, and cell lysates were
generated. For the immune precipitation (IP) assay, 40 μl
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Protein G Sepharose (GE Healthcare, Freiburg, Germany)
was mixed with 2 μg anti-flag antibody for 4 h at 4 °C and
subsequently incubated with 1 mg lysate in 1 ml RIPA buf-
fer overnight, rocking at 4 °C with three times washing
using cold PBS in between. The sepharose was then
washed three times with RIPA buffer and resuspended in
Laemmli/RIPA solution. After denaturation, bound pro-
teins were separated and prepared for Western blotting.
MTT assay
32D cells were plated in triplicate at a density of 3 ×
104 cells/well in a 96-well plate after washing twice with
PBS. The JAK inhibitor ruxolitinib was added to the
medium (max. vol. of 100 μl) at the concentration of
1 μM. Controls were treated with DMSO. Cells were
cultured in WEHI-free RPMI medium. The measure-
ment of cell viability was performed 48 h later using
10 μl 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) (5 mg/ml H2O) per well. The 96-well
plate was incubated in the dark at room temperature for
4 h, and 100 μl isopropanol-HCl solution per well was
added. Samples were analyzed with a microplate reader at
a wavelength of 550 nm (Kayto, RT-2100C).
RT-qPCR
RNA isolation was performed by TRIzol/chloroform ex-
traction (Trizol, Life Technologies, Darmstadt, Germany)
using 6 × 106 cells. One microgram RNA was used for
cDNA synthesis. Quantitative RT-PCR was performed
using the 7500 Fast Real-time PCR System (Applied Bio-
systems by Life technologies, Paisley, UK) with the SYBR
Select Master Mix for CFX (Applied Biosystems). The
sequences of primers used for RT-qPCR were as follows:
GCGTAACAAAGGCAGCAGAG (CALR for), CGTCGT
CGTCCTTGTAGTC (CALR-flag rev), GTGAGTCCCCT
AGCTTGCTG (mu c-Mpl for), TAGCAGGTGTGAAC
GACAGG (mu c-Mpl rev), CCAATACGGCCAAATCCG
(mu Gapdh for), CCAATACGGCCAAATCC (mu Gapdh
rev), ACAGGTGCCTGAAAGGTTGC (mu Nfe2 for),
and ACCCTGCAGCTCAGTAATGG (mu Nfe2 rev). The
mRNA expression level of the target gene is determined
in percentage of Gapdh using 2^-ΔCT.
Concentration of 32D supernatant
32D MPL transduced cells expressing CALR WT or del52
were starved in FBS and WEHI-free RPMI medium at the
density of 2 × 106 cells/ml after washing twice with PBS.
After starvation for 6 h, the cell viability was analyzed by
cell analyzer CASY TTC (OLS, OMNI Life Science,
Bremen, Germany) and the supernatant was collected and
filtered (0.45 μM filter) to the concentrator Vivaspin 20
(Sartorius Stedim Biotech, Goettingen, Germany) followed
by spinning at the speed of 4000×g at 4 °C for 30 min.
Around 3.5 or 12 μg protein of the supernatant was used
for the analysis of paracrine signaling, respectively.
Statistical analysis
Statistical analysis was performed with the GraphPadPrism
software using the two-tailed Student’s t test. Significant
differences were determined by *P < .05, **P < .01, and
***P < .001; mean and standard deviation (SD) are indi-
cated. The results are representative of at least three
independent experiments.See Additional file 1 for sup-
plementary material & methods.
Results
JAK-dependent spontaneous transformation of 32D del52
CALR cells
We analyzed the effect of stable ectopic expression of
the two most prominent CALR mutants (type 1: del52,
type 2: ins5) using IL3-dependent 32D and Ba/F3 cells,
and analysis of these cells confirmed previous reports
that this did not induce growth factor-independent pro-
liferation in the majority of cells [14, 17]. However, after
5 days of starvation, a subpopulation of CALR del52 ex-
pressing 32D cells began to grow cytokine independently
(Fig. 1a), and this was accompanied by increasing STAT5
phosphorylation (Fig. 1b). Moreover, these outgrown
cells were sensitive to the JAK1/2 inhibitor ruxolitinib
(Fig. 1c, d) which abrogated the growth of these cells
completely (Fig. 1e). We did not observe outgrowth of a
CALR ins5 mutant or CALR WT cell population.
Western blot analysis, using a CALR mutant-specific
antibody [18], demonstrated the presence of the ectopi-
cally expressed CALR mutants, with the expression of
ins5 being considerably lower than that of the del52
mutants (Fig. 1b). STAT5 phosphorylation was solely
detected in the outgrown cell subpopulation (Fig. 1b).
Upregulation of the megakaryocytic transcription factor
NF-E2 in CALR-mutant cells
CALR mutations are restricted to MPN subtypes display-
ing aberrant megakaryopoiesis, such as ET, PMF, and post
essential thrombocythemia-myelofibrosis (post-ET-MF)
[3]. Megakaryopoiesis is regulated by megakaryocytic tran-
scription factors as inducers of megakaryocytic differenti-
ation and transcriptional activators of the Mpl promoter
[19–22]. Therefore, we studied whether the expression of
the megakaryocytic transcription factor NF-E2 was af-
fected by the CALR mutants and whether it was increased
in the outgrown 32D del52 cells.
Interestingly, we detected a significant increase of Nfe2
mRNA expression in the del52- and ins5-mutant ex-
pressing cells as well as the outgrown 32D del52 cells,
when compared to 32D cells ectopically expressing WT
CALR (Fig. 2a). We confirmed an increase of NF-E2 at
the protein level in CALR del52 outgrown cells and to a
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lesser extent in del52 expressing cells, while ins5 mutant
expressing cells showed no elevated NF-E2 protein
(Fig. 2b). We generated human HL-60e cells expressing
empty vector, WT CALR, CALR del52, or ins5 mutant
to evaluate the findings in 32D cells (Fig. 2c). In these
cells, WT CALR was detected not only by the conven-
tional CALR antibody but also by the mutant-specific
antibody, which was potentially due to drastic protein
overexpression. The del52-induced increase of NF-E2
protein was confirmed in the stably transduced HL60e
cells (Fig. 2d). Other transcription factors involved in
megakaryopoiesis, such as Gata1, Fli-1, and Ets-1 [20, 23],
were not consistently altered, although Gata1 mRNA was
significantly increased in del52-, ins5-, and outgrown
del52-mutant 32D cells (Additional file 2: Figure S2a, b, c).
We conclude that forced expression of CALR mutants
alone is sufficient to induce upregulation of the megakar-
yocytic transcription factor NF-E2.
CALR mutants trigger the expression of Mpl and CD41 in
32D cells
Having shown that NF-E2 was upregulated by CALR mu-
tant expression, especially in the 32D outgrown del52 cells,
we hypothesized that MPL expression may be upregulated
in the CALR-mutant 32D cell lines as well as in the
outgrown cells. Therefore, we analyzed endogenous
Mpl expression in the transduced 32D cells and ob-
served a significant increase of Mpl mRNA in the
32D del52 and ins5 mutant cells and in the outgrown
del52 mutant cells (Fig. 3a). Interestingly, when we
analyzed the expression of two other type-I cytokine
receptors in del52 vs outgrown del52 cells, the EPO
receptor (EPOR) and the G-CSF receptor (G-CSFR),
known to be necessary for JAK2 V617F transforming
activity [24], we detected a significant decrease of Epo
receptor mRNA in the outgrown 32D del52 cells
(Additional file 2: Figure S2d), while no Gcsf receptor
mRNA was detected. Furthermore, we observed a sig-
nificantly higher expression of endogenous Mpl, when
we overexpressed human MPL in the 32D CALR cell
lines with an emphasis on del52 expressing cells
(Additional file 2: Figure S2e).
Moreover, flow cytometry confirmed increased surface
expression of the integrin CD41 (Fig. 3b), a differentiation
marker for megakaryocytes and platelets and a target gene
of GATA, MAFB, and NF-E2 transcription factors [25, 26].
Ectopic MPL expression also increased CD41 surface ex-
pression; however, this occurred specifically in del52 and
Fig. 1 Spontaneously outgrown 32D CALR del52 cells are ruxolitinib (Ruxo) sensitive. a We performed growth assays with stably transduced 32D
cells expressing empty vector (EV), WT CALR, del52 or the ins5 mutants (2 × 105 cells/ml). Outgrowth of a CALR del52 expressing clone has been
observed after 6 to 10 days. b 32D EV, CALR WT, CALR del52, CALR ins5, and outgrown del52 cells were starved for 16 h; lysates were prepared
and subjected to SDS-PAGE and Western blotting. Indicated antibodies have been used for immunostaining. c Outgrown 32D CALR del52 cells
were treated overnight with 1 μM Ruxo, and reduction of STAT5 phosphorylation could be detected in Western blotting. d In a MTT assay, outgrown
32D CALR del52 cells were treated with 1 μM Ruxo for 48 h, and cell viability was evaluated. The experiment was performed in triplicates. SD is indicated.
**P< 0.01 e Outgrown 32D del52 cells were grown in WEHI-free medium (2 × 105 cells/ml) supplemented with 1, 2, and 3 μM Ruxo or DMSO as control
for up to 72 h. The cells were counted every 24 h. The experiment was performed in triplicates. SD is indicated
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ins5 CALR-mutant but not WT CALR expressing or con-
trol cells (Fig. 3c). Thus, we hypothesize that CALR frame-
shift mutants alone initiate the differentiation towards the
megakaryocytic lineage, which is then promoted by en-
hanced MPL activity. However, CALR mutants alone usu-
ally appeared unable to induce enough Mpl to transform
cells to growth factor independence.
CALR mutants show low protein stability, proteasome-
independent degradation, and stabilization by MPL
expression
We observed significantly lower protein amounts of
CALR del52 and ins5 mutants than WT CALR protein
in cellular lysates of transduced cells (Fig. 1b) although
CALR mRNA was highly expressed (Fig. 4a). This was
observed when Western blotting was performed using
an antibody recognizing either the CALR C-terminus
or the FLAG-tag but not when using a CALR mutant-
specific antibody, suggesting that the mutant CALR pro-
teins had undergone a conformational change. CALR ins5
mRNA and protein expression were consistently lower
than that of del52 (Fig. 1b and Fig. 4a). We generated a C-
terminal truncation mutant (ΔC, truncation of the entire
novel C-terminal part in del52 mutant) and confirmed
CALR antibody binding, showing that the specific epitope
of the antibody is present in the CALR del52 and ins5 mu-
tants (Additional file 3: Figure S3a). To evaluate the possi-
bility of rapid proteasomal degradation of mutant CALR,
Fig. 2 32D cells expressing CALR mutants show increased mRNA and protein levels of the megakaryocytic transcription factor NF-E2. a Detection
of Nfe2 mRNA expression by RT-qPCR in the indicated 32D cells. The experiments were performed in triplicates. SD is indicated. *P < 0.05, **P < 0.01,
***P < 0.001. b Lysates were prepared of 32D cells expressing WT CALR, del52, and ins5 mutant as well as of outgrown 32D del52 cells, and NF-E2
protein was detected in Western blotting. In b and d, GAPDH served as loading control and was used for the calculation of NF-E2 expression ratios.
c HL60e EV (empty vector), CALR WT, CALR del52 and CALR ins5 cells were used to prepare lysates, and SDS-PAGE and Western blotting were performed.
Indicated antibodies have been used for immunostaining. CALR mut antibody showed unspecific binding to ectopic WT CALR. d HL60e cells expressing
empty vector (EV), WT CALR, del52, or ins5 were analyzed for NF-E2 expression, and expression ratios were calculated as in b
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Fig. 3 (See legend on next page.)
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Fig. 3 Endogenous Mpl as well as CD41 was upregulated by CALR-mutant expression. a RT-qPCR was used to detect Mpl mRNA amounts after
RNA isolation of the indicated 32D cells followed by cDNA synthesis. Expression is depicted in percentage to Gapdh. Measurements were done in
triplicates. SD is indicated. *P < 0.05 b FACS analysis of membrane-localized CD41 in the indicated 32D cell lines. Relative expression intensity was
calculated using the mean fluorescent intensity (MFI) of triplicates. SD is indicated. ***P < 0.001 c As in b, the amount of CD41 was evaluated in
32D MPL cells expressing empty vector, WT CALR, del52, or ins5 using FACS. The experiment was performed in triplicates and the SD is
indicated. ***P < 0.001
Fig. 4 (See legend on next page.)
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we treated 32D cells with MG132, a proteasomal inhibitor
(Fig. 4b). However, this did not lead to an increase of
CALR del52 protein but rather a decrease, while WT
CALR protein levels remained stable. We used pSTAT5
staining as a positive control for successful proteasomal
inhibition by MG132, as published [27, 28]. Furthermore,
ubiquitination of WT CALR and the del52 mutant was
not different (Fig. 4c). Next, we analyzed if autophagoso-
mal/lysosomal degradation was the reason for low CALR
mutant abundance. We treated the 32D CALR cell lines
with the autophagy inhibitor spautin-1 to block the fusion
of autophagosomes with lysosomes. The block of the
conversion from LC3B I to II served as control for suc-
cessful autophagy inhibition. No increase of mutant CALR
protein was observed upon inhibition of autophagy
(Fig. 4d). To exclude the possibility that the lack of CALR
mutant protein detection was due to an artifact in
denaturing SDS gels, native PAGE gels were used, show-
ing that detection of mutant CALR was not improved in
native PAGE analysis (Additional file 3: Figure S3b).
Simultaneous ectopic expression of human MPL in-
duced cytokine-independent proliferation and suppressed
apoptosis in 32D cells ectopically expressing CALR del52
or the CALR ins5 mutant but not empty vector (EV)- and
CALR WT-transduced 32D cells (Additional file 4: Figure
S4a, b), as has been described previously [11–14]. No
cytokine-independent proliferation and activated down-
stream signaling was observed by simultaneous ectopic
expression of human EPOR (Additional file 4: Figure S4c,
d). Starved 32D MPL cells expressing CALR mutants but
not CALR WT showed constitutive phosphorylation of
STAT5, STAT3, AKT, and ERK1/2 (Fig. 4e), and cells did
not respond to recombinant TPO unless they overex-
pressed MPL (Additional file 4: Figure S4e). TPO-induced
ERK1/2 phosphorylation was slightly increased in 32D
del52 mutant cells in the absence of ectopic MPL expres-
sion, consistent with increased endogenous MPL expres-
sion, as suggested by the observed elevated mRNA levels
(Fig. 3a). MPL protein was not evaluable due to lack of
suitable antibodies. Protein levels of del52 and ins5 CALR
were hardly detectable, using the flag and the overall
CALR antibody, while WT CALR was readily detected
(Fig. 4e). Importantly, MPL expression led to an increase
of del52 and ins5 protein (Fig. 4e; CALR mut). A similar
effect was observed in the outgrown 32D del52 CALR
cells (Fig. 1b), again confirming our data of Mpl upregula-
tion in the outgrown cells (Fig. 3a). Furthermore, the
expression of del52 and ins5 mutants in 32D cells without
exogenous MPL led to slightly increased AKT phosphor-
ylation (Fig. 4e).
We conclude that CALR mutants are less detectable
than their WT counterparts. This may either be due to
decreased protein stability of CALR mutants or changes
in protein structure that may prevent efficient binding of
CALR antibody or the flag-specific antibody. MPL sig-
nificantly enhanced protein detection of CALR mutants
(Fig. 4e).
Block of membrane trafficking and protein glycosylation
inhibits CALR mutant-induced MPL signaling and
increases cytoplasmic CALR mutant protein
We and others have shown that the constitutively active
receptor tyrosine kinase (RTK) FLT3-ITD activates STAT5
in the ER independently from its status of glycosylation
[29, 30]. We asked whether MPL glycosylation and intra-
cellular trafficking to the plasma membrane is necessary
for CALR mutant-mediated MPL/JAK activation. There-
fore, we treated 32D MPL cells expressing EV, CALR WT,
del52, or ins5 with BFA. BFA has been shown to cause re-
direction from Golgi to the ER and disassembly of the
Golgi apparatus as well as blocking of complex asparagine
(N-) glycosylation [31]. In addition, tunicamycin was used
to completely abolish N-glycosylation of proteins. After
8 h of BFA (5 μg/ml) or tunicamycin (10 μg/ml) treatment,
phosphorylation of STAT5, STAT3, AKT, and ERK1/2 was
strongly reduced, highlighting the importance of MPL gly-
cosylation for CALR mutant-triggered downstream signal-
ing (Fig. 5a).
Interestingly, BFA but not tunicamycin treatment sig-
nificantly enhanced the amount of del52 and ins5 mu-
tant protein in the whole cell lysates, as compared to
vehicle treatment (Fig. 5a; CALR mut). We considered
(See figure on previous page.)
Fig. 4 Degradation of instable CALR mutants is proteasome-independent and mutants get stabilized by MPL expression. a The expression of indicated
CALR-flag constructs in 32D cells +/− ectopic MPL was confirmed by RT-qPCR. The expression is depicted as percentage to Gapdh. Experiments were
performed in triplicates. Mean and SD are indicated. **P< 0.01, ***P< 0.001. b 32D empty vector (EV), WT CALR-positive, or del52-positive cells were treated
with 10 μM MG132 for indicated periods of time. Afterwards, cells were starved in WEHI-free medium for 4 h and lysates were prepared for SDS-PAGE and
Western blotting. Indicated antibodies were used for immunodetection to show protein stability. c HEK293T cells were transfected with HA-
tagged ubiquitin and the indicated CALR-flag constructs. After 24 h, 10 μM MG132 was added for 20 h and protein lysates were prepared.
Immunoprecipitation (IP) was performed with flag antibody followed by SDS-PAGE and Western blotting. In addition, whole cell lysates were
used for Western blotting. d Autophagosomal inhibition was performed in 32D EV, WT CALR, del52, and ins5 expressing cells. The 32D cell
lines were treated with the inhibitor spautin-1 for the indicated time. Lysates were prepared, and SDS-PAGE and Western blotting were performed.
Antibodies detecting mutated CALR (CALR mut), CALR, LC3I-II, and GAPDH were used for immunostaining. LC3I-II served as control for successful
autophagosomal inhibition. e 32D cells expressing EV, WT CALR, del52, or ins5 mutant +/− MPL receptor were starved overnight. Lysates were prepared
and subjected to SDS-PAGE and Western blotting. The PVDF membrane was subjected to the indicated antibodies
Han et al. Journal of Hematology & Oncology  (2016) 9:45 Page 9 of 14
an increased secretion of CALR del52 and ins5 to be the
reason for the low protein amount of CALR mutants in cel-
lular lysates. Therefore, we collected the supernatant and
the cell pellets of WT CALR or del52 expressing 32D MPL
cells after addition of BFA or methanol control for 6 h.
Again, we detected an increase of del52 mutant in the cel-
lular lysates after BFA vs. vehicle treatment (Fig. 5b). Fur-
thermore, we observed higher amounts of del52 in the
supernatant in comparison to lysates, confirming a high se-
cretion rate of CALR del52 (Fig. 5b; CALR mut, -BFA).
WT CALR showed an equal extra- and intracellular pattern
of distribution. DNMT3B (DNA (cytosine-5-)-methyltrans-
ferase 3 beta) staining confirmed the absence of contamin-
ation of the supernatant by cellular proteins.
To differentiate whether low CALR protein detection
in CALR-mutant cells was due to low stability of the
protein or due to low affinity of the CALR antibody, we
fused WT CALR, del52, and ins5 proteins C-terminally
to YFP and generated stably expressing 32D MPL cells.
After sorting for high YFP levels in 32D MPL cells,
del52 CALR-YFP and ins5 CALR-YFP cells were out-
competed by their normal WT CALR-YFP counterparts
Fig. 5 Glycosylation of MPL is essential for the activatory mechanism of CALR mutants, which are strongly secreted. a Empty vector (EV), WT CALR, del52,
and ins5 expressing 32D MPL cells were treated with tunicamycin (T; 10 μg/ml), brefeldin A (B; 5 μg/ml), or the solvent methanol (Me) as control. Lysate
preparation, SDS-PAGE, and Western blotting were performed. Indicated antibodies were used to confirm downstream signaling and CALR expression.
GAPDH staining served as loading control. b Concentrated supernatants (30 μg protein) of indicated 32D cells, which were treated for 6 h with 5 μg/ml
BFA or left untreated, were applied to SDS-PAGE followed by Western blotting and compared to the appropriate cellular lysates (30 μg protein). c 32D
MPL cells expressing C-terminally YFP-tagged WT CALR, del52, or ins5 were FACS sorted for equal YFP-intensities and YFP signal was monitored until
10 days after sorting. Strong decrease of CALR del52-flag-YFP and ins5-flag-YFP could be observed
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(Fig. 5c). At the same time, YFP-tagged CALR del52 in
32D MPL cells still activated STAT5 and conferred
factor-independent cell growth (Additional file 5: Figure
S5a, b). These results show that CALR del52 and ins5
proteins exhibit decreased stability, most likely together
with increased secretion of del52-YFP and ins5-YFP
protein.
WT CALR has been published to be secreted into the
extracellular matrix and to have immune-modulatory
functions [9, 32]. Because of our observation of highly
secreted CALR mutant protein and its ability to interact
with MPL, which had been also documented by Araki et
al. and Marty et al. [12, 13], we analyzed possible para-
crine signaling of the CALR del52 mutant protein. To
do this, we added concentrated supernatant of 32D MPL
CALR del52 cells onto 32D −/+ MPL cells expressing
WT CALR. After 30 min and 16 h, we did not detect
any activation of STAT5 or STAT3 in the exposed cells
(Fig. 6a). In addition, 32D MPL del52 cell supernatant
had no influence on the viability of 32D MPL WT CALR
cells in IL3-free medium using an MTT assay (Fig. 6b).
Discussion
In this study, we demonstrate the capability of the most
frequent CALR type 1 and type 2 frameshift mutants to
induce an increase of endogenous Mpl, CD41, and Nfe2
expression in 32D cells, suggesting that these mutants
may prime hematopoietic stem cells for megakaryocytic
differentiation. Endogenous MPL, CD41, and NF-E2
mRNA and protein expression was increased by CALR
del52 even in the absence of ectopic human MPL ex-
pression as well as in spontaneously outgrown 32D
del52 CALR cells (Figs. 2 and 3; Additional file 2: Figure
S2d). Although we cannot fully exclude a CALR del52-
independent effect in the outgrown cells, the fact that
spontaneous outgrowth occurred in our own experi-
ments as well as in those published by Klampfl et al. [2]
suggests that CALR del52 was responsible for the out-
growth of 32D cells. The increase of Mpl expression and
stabilization of CALR del52 protein in the outgrown
cells suggests that cytokine independence and ruxolitinib
sensitivity were induced by similar mechanisms as in the
CALR mutant-transduced 32D cells ectopically overex-
pressing MPL. Using Sanger sequencing, we excluded
activating mutation in the Jak2 (e.g., V617F) or c-mpl
(e.g., W506L) gene in the outgrown 32D cells. Neverthe-
less, we cannot exclude the possibility that cells with
spontaneously higher MPL or NF-E2 levels were selected
in the presence of the CALR mutants, as opposed to
direct Mpl and Nfe2 induction by the CALR mutants.
There were differences between del52- and ins5-mutant
expressing cells: MPL expression was inconsistent in CALR
ins5 mutant expressing 32D cells (Fig. 3a and Additional
file 2: Figure S2e), and GATA-1 mRNA levels did not
correlate with protein except for 32D CALR ins5 cells
(Additional file 2: Figure S2 c). In general, the effect of ins5
was less prominent than that of del52 except for CD41
upregulation. No outgrowth of 32D CALR ins5 cells was
observed, potentially due to low protein expression. How-
ever, the weaker effect of ins5 mutants may also be due to
negatively charged amino acids in the C-terminus which
are missing in del52. Together, these differences may also
at least in part explain clinical data that have associated
ins5 mutants with a less severe phenotype than CALR
del52 [12].
Our data suggest that CALR del52 and ins5 increase
megakaryocytic differentiation by the alteration of the
transcriptional program, although we can only illustrate
the initializing components of megakaryocytic differenti-
ation in our model system. These data are in line with
Fig. 6 Secreted CALR del52 protein shows no paracrine function in 32D MPL cells. a 32D WT CALR +/− MPL cells were cultured with the
indicated supernatants (12 μg of protein) for 30 min or 16 h before preparation of lysates to analyze STAT5 and STAT3 phosphorylation in
Western blotting. b MTT assays were performed to analyze viability of 32D WT CALR +/− MPL cells cultured in FBS and WEHI-free medium for
48 h treated with the indicated supernatants (3.5 μg/100 μl). Relative viability in percent was calculated by determination of the values gained by
the 32D MPL WT CALR cells + del52 supernatant approach as 100 %
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observations from Marty et al. in a retroviral mouse
model of CALR mutants resulting in an ET and post-
ET-MF phenotype [12] and are supported by a recent
study of Nivarthi et al. [33]. It is known that megakar-
yocytes arise from bipotent megakaryocytic-erythroid
progenitors (MEP) [20]. Therefore, the reduction of
EpoR mRNA together with the increase of Mpl that we
observed in the outgrown 32D del52 cells suggests a
differentiation shift from the erythrocytic to the mega-
karyocytic lineage.
How the CALR mutants del52 and ins5 led to the upreg-
ulation of megakaryocytic markers in 32D cells is not clear,
but we detected an increase of AKT phosphorylation in
del52 and ins5 expressing 32D cells in the absence of ec-
topic MPL expression (Fig. 4e). It was reported that active
AKT positively influences megakaryopoiesis [34, 35]. In
addition, the knockout of the negative regulator of PI3K/
AKT activity PTEN results in a significant increase of
platelets [36]. Therefore, active AKT could be an important
mediator of CALR mutant-induced effects in our cell sys-
tem and in hematopoietic stem cells/megakaryocytes.
CALR del52 and ins5 proteins showed low abundance,
and we were able to exclude ubiquitin-triggered protea-
somal degradation (Fig. 4b, c). In addition, our data sug-
gests that autophagy or lysosome-dependent degradation
[37] were not involved (Fig. 4d). Furthermore, decreased
protein stability was substantiated by our novel YFP fusion
CALR mutants (Fig. 5c). Experiments from Chachoua et
al. using cycloheximide had already suggested decreased
protein stability [11], which seems to be due to the pres-
ence of the new C-terminal domain [17]. We demonstrated
that degradation was partially antagonized by overexpres-
sion of MPL, suggesting a stabilizing effect of MPL on
CALR mutants, together with reduced CALR mutant pro-
tein secretion due to strong MPL interaction, described
here and by Araki et al. [13]. This resulted in enhanced
CALR mutant protein detection in cellular lysates (Fig. 4e;
Additional file 4: Figure S4e). Similar stabilization has been
observed in the outgrown 32D del52 cells (Fig. 1b).
Chachoua et al. had mutated all four N-glycosylation
sites in the extracellular domain of MPL and shown strong
reduction of STAT5 transcriptional activity in the presence
of CALR mutants [11]. Therefore, it is tempting to specu-
late that binding of CALR mutants to the glycosylated
TPO receptor in the lumen of the ER, Golgi, and transport
vesicles may trigger receptor dimerization and JAK activa-
tion. Importantly, and in line with this hypothesis, we have
observed a significant increase of CALR mutant protein
upon BFA treatment of 32D MPL cells, while no increase
of WT CALR was detected. BFA blocks the anterograde
transport from the ER to the Golgi apparatus, leading to
the collapse of Golgi stacks and accumulation of proteins
in the ER [38, 39]. Consequently, it prevents protein secre-
tion [40]. Tunicamycin treatment had no effect on del52
detection, maybe due to tunicamycin-induced unfolded
protein response triggering ER-associated protein degrad-
ation (ERAD) [41].
We detected higher amounts of secreted CALR del52
mutant in the supernatant in comparison to whole cell
lysates, which was blocked by BFA treatment (Fig. 5b). It
is commonly accepted, albeit still a matter of debate,
that WT CALR mediates cellular function from the cell
surface and extracellular matrix, although the exit chan-
nels from the ER are still unknown [9]. Importantly, ER
depletion of Ca2+ led to increased secretion and mem-
brane localization of WT CALR [42, 43]. The occurrence
of mutant CALR alters calcium homeostasis [10, 32],
which could be one of the reasons for the observed in-
crease of CALR mutant secretion. In addition, the KDEL
sequence of WT CALR needs to be masked, negligible
in CALR mutants. Although CALR mutants lack the ER
retention signal KDEL, their localization is still primarily
in the ER and Golgi apparatus, due to the ER-signal
sequence in the N-terminus, where the MPL presumably
gets activated [1, 11]. Nevertheless, activation of glyco-
sylated membrane-standing MPL by CALR mutants can-
not be excluded.
A paracrine function of CALR mutants in neighboring
cells was hypothesized, as discussed already for WT CALR
[9]. Nevertheless, in our experiments as well as in the
work of Araki et al., no paracrine signaling of mutant
CALR was detected [13]. As this absence of paracrine sig-
naling could be due to low CALR mutant concentration
in the supernatant, generation of recombinant CALR-
mutant protein would be of interest. In addition, in vivo
secretion of CALR mutants into the extracellular matrix
of bone marrow and spleen would provide further ways of
action. Thus, intracellular trafficking as well as enhanced
secretion may be the major reasons for the low protein
availability of mutant CALR, most likely in combination
with proteasome-independent CALR mutant degradation.
Conclusions
Our study shows that CALR mutants upregulate the key
megakaryocytic factor NF-E2, the megakaryocytic surface
marker CD41, and the thrombopoietin receptor MPL.
These findings are important in light of the fact that
CALR mutants occur predominantly in essential thrombo-
cythemia and primary myelofibrosis, two malignancies
that are characterized by aberrant megakaryopoiesis. We
determine proteasome- and autophagosome/lysosome-in-
dependent degradation and enhanced secretion as the ex-
planation for low cellular protein abundance and state
MPL-triggered CALR-mutant stabilization. These findings
significantly increase our understanding of CALR-mutant
characteristics and highlight potential mechanisms of ET/
MF pathogenesis.
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Additional file 1: Figure S1. Supplementary material & methods.
Additional file 2: Figure S2. Regulation of megakaryocytic factors by
CALR mutants in murine and human cell lines. a Detection of Fli-1 and
Ets-1 or b Gata1 mRNA expression by RT-qPCR in the indicated 32D and
HL60e cells. The experiments were performed in triplicates. Mean and SD
are indicated. ***P < 0.001. c 32D expressing WT CALR, CALR del52, CALR
ins5 cells, and outgrown 32D del52 cells were used to prepare lysates.
SDS-PAGE and Western blotting were performed. An antibody for the
detection of GATA-1 protein was used for immunostaining. GAPDH
served as loading control and was used for the calculation of GATA-1
expression ratios. d RT-qPCR was used to detect Mpl, EpoR, and G-csfR
mRNA amounts after RNA isolation of the indicated 32D cells followed by
cDNA synthesis. Expression is depicted in percentage to Gapdh. Measurements
were done in triplicates. Mean and SD are indicated. *P< 0.05. e Analysis of
endogenous Mpl expression by RT-qPCR to compare 32D EV, WT CALR, CALR
del52, and CALR ins5 expressing cells +/− ectopic MPL expression.
Experiments were performed in triplicates. Mean and SD are indicated.
**P < 0.01, ***P < 0.001. (PDF 55 kb)
Additional file 3: Figure S3. Missing CALR-mutant detection in Western
blotting is not due to loss of the antibody epitope or an SDS-PAGE artifact.
a HEK293T cells were transiently transfected with expression vectors for flag-
tagged WT CALR, CALR del52, a C-terminal truncation mutant (ΔC; aa R366)
and empty vector. Twenty-four hours after, transfection lysates were
generated and SDS-PAGE followed by Western blotting were performed. The
indicated antibodies were used for immunostaining. The used CALR antibody
bound to the CALR ΔC mutant. b Native page followed by Western blotting
was performed with non-denatured protein lysates of 32D CALR cells. The
PVDF membrane was stained with CALR antibody, and the membrane
was stripped and stained with a flag-specific antibody. (PDF 67 kb)
Additional file 4: Figure S4. Mutant CALR grants factor-independence,
protects from apoptosis, and activates downstream signaling in an MPL-
dependent manner. a A proliferation assay was performed with the indicated
cell lines (2 × 105 cells/ml). 32D MPL cells were counted every 24 h for 4 days.
The cell counts are mean values of triplicates. b Empty vector, WT CALR, CALR
del52, and ins5 expressing 32D cells were seeded in a density of 5 × 105 cells/
ml and grown for 48 h in WEHI-free medium. Apoptosis was analyzed by flow
cytometry after staining with Annexin V-APC and 7-AAD. Mean and SD are
indicated. *P< 0.05, **P< 0.01, ***P< 0.001. c The indicated 32D cell lines were
stably transduced with the EPOR and a proliferation assay was performed (2 ×
105 cells/ml). The cells were counted every 24 h for 4 days. The cell counts are
mean values of triplicates. d After 18 h starvation the indicated 32D cell lines
were stimulated for 15 min with 1 U/ml EPO and lysates were prepared. SDS-
PAGE, Western blotting and immunostaining with the indicated antibodies
was performed. GAPDH served as loading control. e Stably transduced 32D
cells with the indicated CALR-flag constructs +/− MPL were starved for 16 h
and stimulated with 20 ng/ml human TPO for 15 min. Lysates were prepared
and subjected to SDS-PAGE and immunoblotting using antibodies against
phospho-STAT5, phospho-ERK1/2, phospho-STAT3, ERK1/2, STAT5, STAT3, and
mutated CALR (CALR mut). GAPDH served as loading control. (PDF 172 kb)
Additional file 5: Figure S5. Expression of the C-terminally YFP-tagged
CALR del52 mutant leads to STAT5 phosphorylation and cytokine-
independent growth of 32D MPL cells. a 32D cells stably transduced with
WT CALR-flag-YFP, CALR del52-flag-YFP, or empty vector (EV) −/+ MPL
were WEHI-starved for 16 h and protein lysates were prepared. SDS-PAGE
and Western blotting was performed and the indicated antibodies were
used for immunodetection. YFP was detected using a GFP-specific antibody,
and GAPDH served as loading control. b The indicated 32D MPL cells were
cultured in WEHI-free medium (2 × 105 cells/ml). The cells were counted
every 24 h for 3 days. The cell counts are mean values of triplicates.
(PDF 53 kb)
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